Abstract
Colorectal cancer is one of the deadly diseases and is ranked as third for men and second for women amongst all cancers in the world. Due to 6,08,000 deaths, it ranks as the fourth common cause of death due to cancer (WHO, 2018). The “ethnomedicinal studies” of the therapeutic values of plants evolves a systematic scientific evaluation. In the present study, the lead compounds hit on the GCMS analysis of the ethanolic extract of <em>Erythrina variegata</em> L. Leaf. The extract was studied for its anticancer potential in Insilco molecular docking. The results revealed that the 3-eicosyne have strong binding energies against the colorectal cancer mutated oncogene KRAS G12D and tumour suppressor gene p53 R249S in comparison to other compounds. Finally, it is confirmed that the active pharmaceutical ingredients have potent anti-Cancer activity and have great efficacy against the colorectal adenocarcinoma oncogenes and tumour suppressor regulating genes.
Highlights
Cancer is a common cause for mortality, and an over looming threat to mankind[1,2]
To find out the novel active pharmaceutical ingredients (API), Rational Drug Design (RDD) provides the facility but it involves a number of methods, among them docking is one of the best methods because of the process of fitting of a receptor and ligand in 3D space and finding the active site in it[7]
Our present study focused on the ligand receptor interaction of the bio active compound forms the ethanolic extract of Erythrina variegata L. which was docked against the oncogenic and tumour suppressor proteins of colon cancer mutated genes KRAS G12D and P53 R249S respectively
Summary
In developing countries like India, breast cancer is highly prevalent and in years to come the numbers may increase alarmingly due to environmental pollution, changes in lifestyle and inclusion of genetically modified food in the diet[3]. Finding the active pharmaceutical ingredients (API) from the plant is not an easy task[6]. The plant is being used in alternative medicines to treat cancer, very few investigations have evaluated the mechanism of action. To find out the novel API, Rational Drug Design (RDD) provides the facility but it involves a number of methods, among them docking is one of the best methods because of the process of fitting of a receptor and ligand in 3D space and finding the active site in it[7].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
